Sign in
CompletedPhase 3

The Trial of SHR6508 in Secondary Hyperparathyroidism

Key facts

Who runs it
Shanghai Hengrui Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
498 people enrolled
Started
14 Jun 2024
Ended
11 Nov 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SHR6508 plus oral placebo tablets
  • Cinacalcet plus intravenous placebo
Record updated
12 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Able and willing to provide a written informed consent
  • Diagnosed with end stage renal disease receiving maintenance hemodialysis
  • Male or female
  • Meet the Body Mass Index standard
  • Stably use of concomitant medication of other therapies of SHPT
  • Meet the standard of iPTH level, cCa

Who cannot take part

  • Participated in clinical trials of other drugs
  • Subjects with a history of malignant tumor
  • Subjects with neuropsychiatric diseases
  • Subjects with a history of cardiovascular diseases
  • Subjects with gastrointestinal diseases
  • Subjects with a history of surgery
  • Subjects with a history of blood loss
  • Subjects with a treatment history of similar drugs
  • Allergic to a drug ingredient or component
  • Subject with a history of alcohol abuse and drug abuse
  • The investigators determined that other conditions were inappropriate for participation in this clinical trial
  • Abnormal blood pressure, serum magnesium, serum transaminase, serum albumin
  • Pregnant or nursing women
  • No birth control during the specified period of time

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

The 2 groups in the trial

  • Treatment groupTreatment being tested

    Treatment: SHR6508 plus oral placebo tablets

  • Active Control groupExisting treatment, for comparison

    Treatment: Cinacalcet plus intravenous placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Record updated
12 December 2025